Medarex to Receive Milestone Payment from FibroGen
Medarex, Inc. announced it will receive a milestone payment of an undisclosed amount from its licensing partner, FibroGen, Inc., in connection with a recently initiated Phase 2 clinical trial of FG-3019 in patients with type 2 diabetes and advanced kidney disease as announced by FibroGen on June 15, 2009.
FG-3019 is a fully human monoclonal antibody generated using Medarex's UltiMAb(R) technology against connective tissue growth factor (CTGF). Under the agreement with FibroGen, Medarex could receive future milestone payments and sales-based royalty payments.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Scientists discover new type of virus responsible for a devastating disease in snakes

Bacteria reveal strong individuality when navigating a maze
Category:Viperinae
New Pathology Atlas Contains All Cancer Genes To Show Way To Personalised Cancer Treatment - Swedish National Supercomputer Uses Big Data Approach To Show How Cancer Begins And Develops
Santiago_Ramón_y_Cajal
Hybrid_(biology)
Category:Obsolete_taxonomic_groups

New Potential Approach to Treat Atopic Dermatitis
